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Absolute risk and risk factors for stroke mortality in patients with end-stage
kidney disease (ESKD): population-based cohort study using data linkage
Abstract
INTRODUCTION: People with end-stage kidney disease (ESKD) have up to 30-fold higher risk of stroke
than the general population. OBJECTIVE: To determine risk factors associated with stroke death in the
ESKD population. METHODS: We identified all patients with incident ESKD in Australia (1980-2013) and
New Zealand (1988-2012) from the Australian and New Zealand Dialysis and Transplant Registry
(ANZDATA) registry. We ascertained underlying cause of death from data linkage with national death
registries and risk factors from ANZDATA. Using a competing risks multivariable regression model, we
estimated cumulative incidence of stroke and non-stroke deaths, and risk factors for stroke deaths
(adjusted sub-HR, SHR). RESULTS: We included 60 823 people with ESKD. There were 941 stroke deaths
and 33 377 non-stroke deaths during 381 874 person-years of follow-up. Overall, the cumulative incidence
of stroke death was 0.9% and non-stroke death was 36.8% 5 years after starting ESKD treatment. The risk
of stroke death was higher at older ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 1.41, 95% CI
1.21 to 1.64), in people with cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD caused
by hypertensive/renovascular disease (SHR 1.39, 95% CI 1.09 to 1.78) or polycystic kidney disease (SHR
1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39)
and receiving dialysis (transplant vs haemodialysis SHR 0.27, 95% CI 0.09 to 0.84). CONCLUSION:
Patients with ESKD with higher risk of stroke death are older, women, with cerebrovascular disease, with
hypertensive/renovascular or polycystic kidney disease cause of ESKD, with earlier year of ESKD
treatment and receiving dialysis. These groups may benefit from targeted stroke prevention interventions.
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Abstract
Introduction People with end-stage kidney disease
(ESKD) have up to 30-fold higher risk of stroke than the
general population.
Objective To determine risk factors associated with stroke
death in the ESKD population.
Methods We identified all patients with incident ESKD
in Australia (1980–2013) and New Zealand (1988–2012)
from the Australian and New Zealand Dialysis and
Transplant Registry (ANZDATA) registry. We ascertained
underlying cause of death from data linkage with national
death registries and risk factors from ANZDATA. Using
a competing risks multivariable regression model, we
estimated cumulative incidence of stroke and non-stroke
deaths, and risk factors for stroke deaths (adjusted subHR, SHR).
Results We included 60 823 people with ESKD. There
were 941 stroke deaths and 33 377 non-stroke deaths
during 381 874 person-years of follow-up. Overall, the
cumulative incidence of stroke death was 0.9% and
non-stroke death was 36.8% 5 years after starting ESKD
treatment. The risk of stroke death was higher at older
ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR
1.41, 95% CI 1.21 to 1.64), in people with cerebrovascular
disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD
caused by hypertensive/renovascular disease (SHR 1.39,
95% CI 1.09 to 1.78) or polycystic kidney disease (SHR
1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD
treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) and
receiving dialysis (transplant vs haemodialysis SHR 0.27,
95% CI 0.09 to 0.84).
Conclusion Patients with ESKD with higher risk of
stroke death are older, women, with cerebrovascular
disease, with hypertensive/renovascular or polycystic
kidney disease cause of ESKD, with earlier year of ESKD
treatment and receiving dialysis. These groups may benefit
from targeted stroke prevention interventions.

Introduction
Compared with the general population,
people with end-stage kidney disease (ESKD)
have a substantially reduced life expectancy
with cardiovascular disease killing more than
50% of people receiving renal replacement

Strengths and limitations of this study
►► This study used a large, population-based cohort in-

cluding the entire population with end-stage kidney
disease (ESKD) in Australia and New Zealand.
►► The largest multinational study examining risk factors for stroke mortality in people with ESKD to date.
►► Data linkage with the national death registries allowed legal cause of death to be ascertained for
all patients, although probabilistic data linkage for
Australian patients with ESKD may lead to some patients being incorrectly linked.
►► Detailed patient information on the use of stroke
prevention drugs or other factors relating to their
risk of stroke was not available, such as family history of stroke and atrial fibrillation.

therapy (RRT).1–3 Globally in developed countries, mortality from cardiovascular diseases
has declined since the 1960s, with heart disease
deaths declining by 56% in the USA between
1950 and 1996 and all-cause cardiovascular
deaths declining by more than 70% in the
Netherlands and 60% in the UK and Ireland
from 1980 to 2009. Despite people with ESKD
having a 5 to 30-fold increased risk of stroke
compared with the general population, the
epidemiology of stroke death in ESKD is far
less clear. An Australian registry-based study
reported that for people with ESKD, the relative risk of death from cardiovascular disease
between 1992 and 2005 increased compared
with the general population, despite absolute
cardiovascular death rates falling.4 Another
contemporary Taiwanese case–control study
reported a greater than twofold risk of 30-day
mortality following a stroke in people with
ESKD compared with propensity-matched
controls.5
Such differences in outcomes between the
general population and people with ESKD
following a stroke could arise because of
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Method
Study design and setting
We performed a population-based cohort study of all
adults and children starting RRT for treatment of ESKD in
Australia (1 January 1980 to 31 December 2013) and New
Zealand (1 January 1988 to 31 December 2012). Australia
(population 24.8 million in 2017) and New Zealand
(population 4.7 million in 2017) are broadly comparable
in racial make-up and population demographics, where
approximately 75% are from a European, Australian or
New Zealand cultural background.11 12 Both countries have
a universal healthcare system that provides free medical
care in public health systems. All deaths occurring in each
country are reported to the Births, Deaths and Marriages
Registry with a medical certificate for the cause of death
completed by a medical doctor which is then coded to the
international standard, the International Statistical Classification of Diseases and Related Health Problems (ICD),
codes by a qualified clinical coder, detailing both the
underlying and secondary causes of death. The underlying cause of death is considered as the disease or condition which initiated the sequence of events resulting in
death. Secondary or contributing causes of death are
other diseases or conditions that contributed to the death
but were not the underlying cause.
Participants, data linkage and death outcomes
People with ESKD
The Australia and New Zealand Dialysis and Transplant
Registry (ANZDATA) prospectively collects data from
all dialysis and transplant centres in Australia and New
Zealand. Data are collected either via web based or
printed survey forms in real time as key events occur
for each patient with ESKD. Core data collected include
2

demographics (age, sex, country, racial background,
body mass index, BMI and smoking history), comorbidities (cerebrovascular disease, diabetes, coronary artery
disease, peripheral artery disease and previous malignancy) and modality of treatment for ESKD (type of
dialysis or transplant, date initiated and cause of kidney
failure). ANZDATA data collection, remit and validation
has been previously described elsewhere.13
Data linkage
We used data linkage of ANZDATA with each of the
national death registries in Australia and New Zealand
to determine the date and underlying cause of death for
people with ESKD. In Australia, patients with ESKD were
linked with the National Death Index, which records all
deaths from 1980 and is maintained by the Australian
Institute of Health and Welfare (AIHW). The Australian Bureau of Statistics (ABS) retrieves information on
all deaths and their causes from the Births, Deaths and
Marriages Registry in each state and territory. The ABS
collates these data and a clinical coder then codes the
causes of death to an international standard ICD.14 The
National Centre for Classification in Health has developed an Australian modification version, currently in its
Tenth Revision which is referred to as ICD-10-AM. We
used probabilistic record linkage for Australian patients
with ESKD, matching on date of birth, sex and full name.
In New Zealand, patients with ESKD were linked with the
Mortality Collection database, which collects information
on all deaths from 1988 and is maintained by the New
Zealand Ministry of Health. The Ministry receives information from the Births, Deaths and Marriages Registry
as well as additional information from medical certificates and coroners’ reports to classify causes of death
into ICD-10-AM. We used deterministic linkage for New
Zealand patients with ESKD, matching on the National
Health Index number. Hence, our analysis was restricted
by the available data in the national death registries. We
included all patients with incident ESKD in Australia
during 1980–2013 and in New Zealand during 1988–2012.
Data linkage was performed by the AIHW and New
Zealand Ministry of Health using best-practice privacy-preserving protocols. After data linkage was complete,
only de-identified data were made available for the
purposes of this study.
Death ascertainment, stroke definition and cause of death
Causes of death were determined using ICD-10-AM diagnosis codes provided in the underlying cause of death
from the Australian and New Zealand national death
registries. All-cause stroke deaths included subarachnoid
haemorrhage (I60.0–I60.9), intracerebral haemorrhages
(I61.0–I61.9), intracranial haemorrhages (I62.0–I62.9),
ischaemic strokes (I63.0–I63.9), unspecified strokes
(I64.0–I64.9) and, transient cerebral ischaemic attacks
and related syndromes (G45.0–G45.9). Prior to 1997,
the ninth revision of ICD was implemented. There is
little evidence for significant differences in stroke coding
De La Mata NL, et al. BMJ Open 2019;9:e026263. doi:10.1136/bmjopen-2018-026263
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differences in the prevalence and severity of underlying
traditional stroke risk factors including hypertension,
diabetes and atrial fibrillation.6 7 Stroke case severity may
also differ, as might the effectiveness and access to preventative treatments (including aspirin, ACE inhibitors, anticoagulants and statins) and acute stroke interventions
including thrombolysis. Risk factors specific to people
with ESKD may also exist: accelerated calcific atherosclerosis (from disordered bone metabolism), platelet
dysfunction, anaemia.1 8 In addition, dialysis-associated
osmotic fluid and electrolyte shifts or exposure to glucose
degradation products from peritoneal dialysis (PD) fluid
may all alter normal pathological glial scar resolution and
affect functional outcomes following stroke.9 For people
with kidney transplants, in addition to traditional cardiovascular risk factors, graft function and albuminuria as
well as the side effects of immunosuppressive medicines
might all modify stroke outcomes.10
The aims of our study were to establish robust estimates
of stroke and non-stroke death incidence in people with
ESKD, and to identify risk factors associated with dying
after a stroke.

Open access

between revisions, with agreement being over 90%.15 16
All other causes of death were considered as non-stroke
deaths.
Patient and public involvement
We used retrospective registry data for this study, hence
study participants were not involved in the recruitment or
design of the study. Patient advisers were also not involved
in this study.
Statistical analyses
We summarised the main causes of death by deriving the
leading causes of death, defined by ICD-10-AM codes.17
We also estimated the crude mortality rates for stroke
and non-stroke deaths, overall and stratified by patient
demographics.
We used Fine and Gray competing risks regression
models to evaluate risk factors associated with stroke
death.18 Time was measured from the start date of ESKD
treatment until a participant died or 31 December 2013
(Australian participants) or 31 December 2012 (New
Zealand participants), whichever came first. As probabilistic record linkage may lead to a small proportion of
incorrect links,19 Australian patients were censored at the
ANZDATA date of death if ANZDATA considered the
patient had died and the national death registry had not
captured any death. For the analysis of stroke deaths, all
non-stroke deaths were considered as competing events.
For comparison, we also similarly conducted an analysis
of non-stroke deaths, with stroke deaths considered as
competing events. For both the stroke and non-stroke
De La Mata NL, et al. BMJ Open 2019;9:e026263. doi:10.1136/bmjopen-2018-026263

Results
Patient characteristics
We identified a total of 62 296 people with incident ESKD
in Australia and New Zealand between 1980 and 2013.
Of these, 1473 New Zealand patients initiated RRT prior
to 1988 or after 2012, and so could not be linked. The
remaining 60 823 patients with ESKD were included in the
analysis (figure 1). The fact of death for the majority of
patients was similar between ANZDATA and the national
death registries, where disagreement occurred for 7.6%
of Australian patients and 5.5% of New Zealand patients.
There were 467 patients considered to be lost to follow-up
in ANZDATA, where 57 patients were considered to have
died in the national death registry. There were 381 874
person-years (PYs) of follow-up, with a median follow-up
time of 4.0 years (IQR 1.7–8.4 years).
During the study period, 26 505 patients (43%)
remained in active follow-up and 34 318 patients (57%)
died (table 1). Of the patients who died, 33 377 patients
died of non-stroke causes (97.3%) and 941 patients
(2.7%) died of stroke. In our entire study population,
two-thirds (69%) were aged 50 years or older at ESKD,
with a median age of 59 years (IQR 46–69). Most were
from Australia (85%), were male (59%), had a Caucasian
background (76%) and had started treatment for ESKD
3
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Figure 1 Patient flow chart of data linkage process and
inclusion into analysis. ANZDATA, Australian and New
Zealand Dialysis and Transplant Registry; ESKD, end-stage
kidney disease.

analyses, we used the same covariates, selected a priori
including: age at initiation of ESKD treatment, sex, year
of initiating ESKD treatment, country, racial background,
BMI category (underweight, ≤18.4 kg/m2; normal, 18.5–
24.9 kg/m2; overweight, 25.0–29.9 kg/m2 and obese,
≥30.0 kg/m2), initial ESKD treatment modality, comorbidities, smoking status and cause of ESKD. Univariable
models were fitted for each covariate, and the multivariable models included all covariates. The cumulative incidence was estimated from the final multivariate model, by
sex and year of initiating ESKD treatment, adjusting for
all other covariates except BMI.
There were no missing data, except for BMI. Missing
values for BMI were imputed using chained equations
with five iterations. To impute, we used the same variables as those used in the competing risks analyses, then
converted those BMI values into categories for the regression models.
We conducted a further three sensitivity analyses to
determine: (1) whether risk factors for any stroke death
were similar to risk factors for fatal ischaemic stroke and
fatal haemorrhagic stroke; (2) whether risk factors were
the same when stroke death was defined as underlying
cause, or secondary cause when kidney failure was indicated as the underlying cause and (3) whether ever transplanted with a kidney as a time-varying covariate produced
different model estimates. For these sensitivity analyses,
we used cause-specific Cox regression models to evaluate
associated risk factors and used the same covariates and
definition of time at risk as described in the main analysis.
Data were analysed using Stata V.14 (Stata).

Open access

Stroke deaths Total

Non-stroke deaths
Total

Total

Characteristics

n (%)*

n (%)*

n (%)*

Total, (%)
Age at RRT initiation (years)

941 (2)†

33 377 (55)†

60 823 (100)

 ≤29

25 (3)

1150 (3)

5088 (8)

 30–49

177 (19)

5399 (16)

13 807 (23)

 50–64

329 (35)

11 417 (34)

19 980 (33)

 65–74

261 (28)

9658 (29)

13 842 (23)

 ≥75

149 (16)

5753 (17)

8106 (13)

 Median (IQR)

62 (52–71)

63 (53–72)

59 (46–69)

Sex
 Female

472 (50)

13 901 (42)

25 042 (41)

 Male

469 (50)

19 476 (58)

35 781 (59)

 ≤1995

379 (40)

11 515 (35)

15 382 (25)

 1996–2005

367 (39)

14 700 (44)

22 115 (36)

 2006–2013

195 (21)

7162 (21)

23 326 (38)

 Australia

819 (87)

28 173 (84)

51 451 (85)

 New Zealand

122 (13)

5204 (16)

9372 (15)

 European

737 (78)

26 286 (79)

46 025 (76)

 Indigenous Oceania

Year of ESKD

Country

Racial background
122 (13)

5244 (16)

9743 (16)

 Asian

78 (8)

1667 (5)

4357 (7)

 African and Middle East

4 (<0.5)

 Peoples of the America

0 (−)

4 (<0.1)

19 (<0.1)

 Other‡

0 (−)

22 (<0.1)

187 (<0.4)

154 (<0.5)

492 (1)

Body mass index
 Underweight (≤18.4)

32 (3)

1274 (4)

2702 (4)

 Normal (18.5–24.9)

353 (38)

10 662 (32)

19 866 (33)

 Overweight (25.0–29.9)

209 (22)

8670 (26)

16 641 (27)

 Obese (≥30)

132 (14)

6561 (20)

13 772 (23)

 Not collected

215 (23)

6210 (19)

7842 (13)

Comorbidities at ESKD
 Cerebrovascular disease

246 (26)

5393 (16)

7676 (13)

 Diabetes

313 (33)

12 863 (39)

21 717 (36)

 Coronary artery disease

372 (40)

14 310 (43)

20 785 (34)

 Peripheral artery disease

252 (27)

9487 (28)

13 373 (22)

 Previous malignancy

208 (22)

9707 (29)

15 788 (26)

 Current/former

413 (44)

16 081 (48)

28 389 (47)

 Never

345 (37)

11 955 (36)

25 861 (43)

 Unknown

183 (19)

5341 (16)

6573 (11)

Cause of renal failure
 Diabetes

249 (26)

9925 (30)

16 909 (28)

Smoking status

Continued
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Table 1 Characteristics of participants with end-stage kidney disease (ESKD), overall and by stroke and non-stroke deaths
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Stroke deaths Total

Non-stroke deaths
Total

Total

Characteristics

n (%)*

n (%)*

n (%)*

 Hypertension/renal artery
disease

169 (18)

4763 (14)

7264 (12)

 Glomerulonephritis/IgA
nephropathy

211 (22)

7626 (23)

16 632 (27)

 Polycystic kidney disease
 Other
Transplanted at beginning of
study
Transplanted during study

71 (8)

1623 (5)

4003 (7)

241 (26)

9440 (28)

16 015 (26)

4 (<0.5)
154 (16)

151 (<0.5)
4978 (15)

1649 (3)
16 068 (26)

*Column percentage.
†Row percentage.
‡Includes Australian Aboriginal, Maori, Torres Strait and Pacific Islander.
RRT, renal replacement therapy.

in 1996 or later (74%). The majority of patients had a
normal (33%) or overweight (27%) BMI, where only 4%
were underweight. The BMI was not collected for 13%
of patients, the large majority (95%) of whom reached
ESKD prior to 1996. The main cause of ESKD was diabetes
(28%), followed by glomerulonephritis/IgA nephropathy
(27%), other causes of ESKD (26%), hypertension/renal
artery disease (12%) and polycystic kidney disease (7%).
The reason for other causes of ESKD included uncertain diagnosis (23%), analgesic nephropathy (18%) and
reflux nephropathy (16%).
Deaths
There were a total of 34 318 deaths since initiation of
ESKD treatment, with a crude rate of 89.9 (95% CI 88.9
to 90.8) per 1000 PYs. The top four leading causes of
death were recorded as diabetes (18%), coronary heart
disease (18%), kidney failure (13%) and glomerular
disease (5%). Stroke was the sixth leading cause of death
since RRT, with a total 941 stroke deaths, corresponding
to a crude rate of 2.5 (95% CI 2.3 to 2.6) per 1000 PYs
(table 2). Stroke deaths were due to: 108 (11%) ischaemic strokes; 259 (28%) intracerebral haemorrhages; 90
(10%) intracranial haemorrhages; 68 (7%) subarachnoid
haemorrhages; 114 (12%) transient cerebral ischaemic
attacks and related syndromes and 302 (32%) unspecified strokes (online supplementary appendix 1).
The highest rate of stroke death since initiation of ESKD
treatment was among those with known cerebrovascular
disease at 9.1 (95% CI 8.0 to 10.3) per 1000 PYs, followed
by those aged 75 years or older at 6.6 (95% CI 5.6 to 7.7)
per 1000 PYs (table 2). In comparison, the highest rate
of non-stroke death since initiation of ESKD treatment
was among those aged 75 years or older at 254.5 (95%
CI 248.0 to 261.2) per 1000 PYs, followed by those with
cerebrovascular disease at 199.0 (95% CI 193.7 to 204.4)
per 1000 PYs.
De La Mata NL, et al. BMJ Open 2019;9:e026263. doi:10.1136/bmjopen-2018-026263

Risk factors for stroke mortality
The multivariable model suggested a higher risk of stroke
death was associated with older age, female sex, earlier
year of ESKD, normal BMI range, presence of pre-existing cerebrovascular disease, no previous malignancy,
ESKD treatment with haemodialysis (HD) compared with
transplant and hypertension/renal artery disease or polycystic kidney disease as the cause of ESKD compared with
glomerulonephritis/IgA nephropathy (table 3).
Older age was associated with a higher risk of stroke
death, where patients aged 75 years or older were 92%
sub-HR (SHR 1.92, 95% CI 1.45 to 2.55) more likely to die
from stroke death compared with those aged 30–49 years
(p<0.001). Females were 41% more likely to die of stroke
death compared with males (SHR 1.41, 95% CI 1.21 to
1.64; p<0.001). There was a decreasing trend in the risk
of stroke death overtime, where patients initiating ESKD
treatment in ≤1995 and 1996–2005 were 93% (SHR 1.93,
95% CI 1.56 to 2.39) and 30% (SHR 1.30, 95% CI 1.09 to
1.55), respectively, more likely to die from stroke death
compared with those in 2006–2013 (p<0.001). Patients
had over two times the increased risk of stroke death if
they had pre-existing cerebrovascular disease (SHR 2.39,
95% CI 1.99 to 2.87; p<0.001) and were 36% less likely to
die of stroke if they had a previous malignancy (SHR 0.64,
95% CI 0.53 to 0.78; p<0.001). There was no difference in
the risk of stroke death for those who initiated PD (SHR
0.85; 95% CI 0.72 to 1.01) compared with HD. However,
transplant patients were 73% less likely to die of stroke
compared with HD patients (SHR 0.27, 95% CI 0.09 to
0.84). Similar estimates for the risk of stroke death were
produced when transplant was considered a time-varying
covariate (HR 0.24, 95% CI 0.17 to 0.32; p<0.001) (online
supplementary appendix 2). The cause of ESKD was also
significantly associated with stroke mortality (p=0.020).
Patients with hypertension/renal artery disease or
5
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2.9 (2.6 to 3.2)

329/114 712

261/53 273

149/22 604

 50–64

 65–74

 ≥75

469/221 874

 Male

195/69 320

 2006–2013

353/128 162

209/92 333

132/63 171

215/76 539

 Normal

 Overweight

 Obese

 Missing

122/50 614

78/29 196

4/3615

 Indigenous Oceania

 Asian

 Other

0.3 (0.1 to 0.8)

652/255 998

4/13 542

 Transplant

 Cerebrovascular disease

Comorbidities at ESKD

2.5 (2.4 to 2.8)

285/112 334

 Peritoneal dialysis

2.5 (2.3 to 2.8)

1.1 (0.4 to 2.9)

2.7 (2.1 to 3.3)

2.4 (2.0 to 2.9)

2.5 (2.3 to 2.7)

2.8 (2.5 to 3.2)

2.1 (1.8 to 2.5)

2.3 (2.0 to 2.6)

2.8 (2.5 to 3.1)

1.5 (1.0 to 2.1)

 Haemodialysis

First dialysis module

737/298 450

 European

Racial background

32/21 669

 Underweight

Body mass index category

2.5 (2.2 to 2.8)

367/147 631

 1996–2005
2.8 (2.4 to 3.2)

2.3 (2.1 to 2.5)

379/164 923

2.1 (1.9 to 2.3)

3.0 (2.7 to 3.2)

6.6 (5.6 to 7.7)

 ≤1995

Year of end-stage kidney disease (ESKD)

472/160 000

 Female

Sex

1.4 (1.2 to 1.6)

177/125 463

 30–49
4.9 (4.3 to 5.5)

0.4 (0.3 to 0.6)

2.5 (2.3 to 2.6)

25/65 822

941/381 874

Rate/1000 person-years
(95% CI)

 ≤29

Age at study entry (years)

Events/person-years

Stroke death

Stroke and non-stroke crude mortality rates (per 1000 person-years) by risk factors

149/13 542

22 735 /255 998

10 493/112 334

180/3615

1667/29 196

5244/50 614

26 286/298 450

6210/76 539

6561/63 171

8670/92 333

10 662/128 162

1274/21 669

7162/69 320

14 700 /147 631

11 515/164 923

19 476/221 874

13 901/160 000

5753/22 604

9658/53 273

11 417/114 712

5399/125 463

1150/65 822

33 377/381 874

Events/person-years

Non-stroke death

11.0 (9.4 to 12.9)

88.8 (87.7 to 90.0)

93.4 (91.6 to 95.2)

49.8 (43.0 to 57.6)

57.1 (54.4 to 59.9)

103.6 (100.8 to 106.5)

88.1 (87.0 to 89.1)

81.1 (79.1 to 83.2)

103.9 (101.4 to 106.4)

93.9 (91.9 to 95.9)

83.2 (81.6 to 84.8)

58.8 (55.7 to 62.1)

103.3 (101.0 to 105.7)

99.6 (98.0 to 101.2)

69.8 (68.6 to 71.1)

87.8 (86.6 to 89.0)

86.9 (85.4 to 88.3)

254.5 (248.0 to 261.2)

181.3 (177.7 to 184.9)

99.5 (97.7 to 101.4)

43.0 (41.9 to 44.2)

17.5 (16.5 to 18.5)

87.4 (86.5 to 88.3)

Continued

Rate/1000 person-years
(95% CI)
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3.4 (3.1 to 3.8)

313/90 865

 Present

252/48 839

 Present

2.3 (2.1 to 2.5)
2.7 (2.5 to 3.0)

528/230 776

413/151 098

 Never/unknown

 Current/former

1.5 (1.3 to 1.7)
2.1 (1.7 to 2.7)

169/29 547

211/140 460

71/33 101

241/107 349

 Hypertension/renal artery
disease

 Glomerulonephritis/IgA
nephropathy

 Polycystic kidney disease

 Other

2.2 (2.0 to 2.5)

5.7 (4.9 to 6.7)

249/71 417

 Diabetes

Cause of renal failure
3.5 (3.1 to 3.9)

1.6 (1.4 to 1.8)

208/131 427

 Present

Smoking status

2.9 (2.7 to 3.1)

733/250 447

 Absent

5.2 (4.6 to 5.8)

9440/107 349

1623/33 101

7626/140 460

4763/29 547

9925/71 417

16 081/151 098

17 296/230 776

9707/131 427

23 670/250 447

9487/48 839

23 890/333 035

14 310/ 79 158

19 067/ 3 02 716

12 863/90 865

20 514/291 009

5393/27 104

27 984/354 770

Events/person-years

Non-stroke death

87.9 (86.2 to 89.7)

49.0 (46.7 to 51.5)

54.3 (53.1 to 55.5)

161.2 (156.7 to 165.8)

139.0 (136.3 to 141.7)

106.4 (104.8 to 108.1)

74.9 (73.8 to 76.1)

73.9 (72.4 to 75.3)

94.5 (93.3 to 95.7)

194.3 (190.4 to 198.2)

71.7 (70.8 to 72.7)

180.8 (177.8 to 183.8)

63.0 (62.1 to 63.9)

141.6 (139.1 to 144.0)

70.5 (69.5 to 71.5)

199.0 (193.7 to 204.4)

78.9 (78.0 to 79.8)

Rate/1000 person-years
(95% CI)
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 Previous malignancy

689/333 035

 Absent

2.1 (1.9 to 2.2)

4.7 (4.2 to 5.2)

372/79 158

 Present

 Peripheral artery disease

1.9 (1.7 to 2.0)

569/3 02 716

 Absent

 Coronary artery disease

2.2 (2.0 to 2.3)

628/291 009

 Absent

 Diabetes

246/27 104

 Present
9.1 (8.0 to 10.3)

2.0 (1.8 to 2.1)

695/354 770

 Absent

Stroke death
Rate/1000 person-years
(95% CI)

Continued

Events/person-years
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Stroke death

Non-stroke death

SHR (95% CI)

P value

SHR (95% CI)

P value

Age at study entry (years)
 ≤29

0.43 (0.26 to 0.70)

<0.001
–

0.39 (0.37 to 0.43)

<0.001
–

 30–49

Ref

 50–64

1.47 (1.16 to 1.86)

–

1.96 (1.89 to 2.04)

–

 65–74

1.82 (1.42 to 2.33)

–

3.23 (3.10 to 3.37)

–

 ≥75

1.92 (1.45 to 2.55)

–

4.68 (4.45 to 4.91)

–

<0.001

1.05 (1.02 to 1.08)

Ref

Sex
 Male

Ref

 Female

1.41 (1.21 to 1.64)

Ref
<0.001

Year of ESKD

<0.001
<0.001

 ≤1995

1.93 (1.56 to 2.39)

–

1.39 (1.33 to 1.45)

–

 1996–2005

1.30 (1.09 to 1.55)

–

1.29 (1.25 to 1.33)

–

 2006–2013

Ref

Ref
<0.001

BMI category

–

<0.001
1.24 (1.16 to 1.33)

–

 Underweight

0.78 (0.54 to 1.12)

 Normal

Ref

 Overweight

0.76 (0.64 to 0.90)

–

0.93 (0.90 to 0.96)

–

 Obese

0.61 (0.49 to 0.76)

–

0.98 (0.95 to 1.02)

–

Ref

Racial background
 Non-white

Ref

Ref

 White

0.88 (0.73 to 1.06)

0.182

1.11 (1.07 to 1.15)

<0.001

2.39 (1.99 to 2.87)

<0.001

1.13 (1.09 to 1.17)

<0.001

1.00 (0.83 to 1.20)

0.960

1.38 (1.34 to 1.42)

<0.001

0.90 (0.74 to 1.09)

0.299

1.30 (1.25 to 1.34)

<0.001

0.64 (0.53 to 0.78)

<0.001

0.90 (0.88 to 0.93)

<0.001

Comorbidities at ESKD
 Cerebrovascular disease
 Present
 Coronary artery disease
 Present
 Peripheral artery disease
 Present
 Previous malignancy
 Present
Smoking status
 Never/unknown

Ref

 Current/former

1.06 (0.91 to 1.24)

Ref
0.441

1.18 (1.15 to 1.21)

0.015

First dialysis module

<0.001
<0.001

 HD

Ref

Ref

 PD

0.85 (0.72 to 1.01)

–

1.00 (0.97 to 1.03)

–

 Transplant

0.27 (0.09 to 0.84)

–

0.26 (0.22 to 0.31)

–

0.020

Cause of renal failure

<0.001

 Diabetes

1.23 (0.99 to 1.54)

–

1.60 (1.54 to 1.66)

–

 Hypertension/
renal artery disease

1.39 (1.09 to 1.78)

–

1.23 (1.18 to 1.29)

–

 Glomerulonephritis/
IgA nephropathy
 Polycystic kidney disease

Ref
1.38 (1.00 to 1.90)

Ref
–

0.72 (0.68 to 0.76)

–
Continued
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Table 3 Summary of the adjusted sub-HR (SHR) estimates for the competing risks model with stroke deaths as the main
event and non-stroke deaths as the competing event

Open access

Stroke death
SHR (95% CI)
 Other

1.03 (0.82 to 1.28)

Non-stroke death
P value
–

SHR (95% CI)
1.42 (1.37 to 1.47)

P value
–

The multivariate model was also adjusted for country. Global p values were test for heterogeneity.
Bold values indicate estimates with a significant association at 0.05 alpha level (ie, p value<0.05).
BMI, body mass index; ESKD, end-stage kidney disease; HD, haemodialysis; PD, peritoneal dialysis.

polycystic kidney disease were 39% (SHR 1.50, 95% CI
1.20 to 1.87) and 38% (SHR 1.38, 95% CI 1.00 to 1.90),
respectively, more likely of stroke death compared with
those with glomerulonephritis/IgA nephropathy. The
unadjusted estimated risk of stroke death is presented in
online supplementary appendix 3.
In the sensitivity analysis, the risk of fatal ischaemic
stroke was not associated with BMI, cerebrovascular
disease, previous malignancy or HD compared with transplant (online supplementary appendix 4). White racial
background and coronary artery disease were associated
with an increased risk of ischaemic stroke death, which
were not risk factors for all-cause stroke death. Year of
ESKD was also not associated with the risk of fatal ischaemic or haemorrhagic stroke. The risk factors for fatal
haemorrhagic stroke were all similar to the risk factors
for all-cause stroke death, except for cause of renal failure
(online supplementary appendix 4). Cause of renal
failure was not associated with the risk of fatal haemorrhagic stroke.
There were an additional 694 stroke deaths when
all-cause stroke death was defined as the underlying cause
or secondary cause when kidney failure was the underlying cause. All risk factors associated with the extended
definition for all-cause stroke were the same as those
identified in the main analysis, except for peripheral
artery disease (online supplementary appendix 5). In the
sensitivity multivariate model, patients with pre-existing
peripheral artery disease were at an increased risk for
all-cause stroke mortality.
Risk factors for non-stroke mortality
The multivariable model suggested that a higher risk of
non-stroke death was associated with older age, female
sex, earlier year of ESKD, underweight or normal BMI
range, Caucasian background, presence of comorbidities including cerebrovascular disease, coronary artery
disease, peripheral artery disease and no previous malignancy, current or former smoker, dialysis compared with
transplant and cause of ESKD including diabetes, hypertension/renal artery disease or other causes (table 3).
Patients initiating ESKD treatment with a transplant
were associated with a 73% lower risk of non-stroke death
compared with those initiating HD (SHR 0.27, 95% CI
0.23 to 0.32; p<0.001). Similar estimates for the risk of
non-stroke death were produced when transplant was
considered a time-varying covariate (HR 0.30, 95% CI
0.29 to 0.32; p<0.001) (online supplementary appendix
De La Mata NL, et al. BMJ Open 2019;9:e026263. doi:10.1136/bmjopen-2018-026263

2). The cause of ESKD was also significantly associated
with non-stroke mortality (p<0.001). A higher risk of
non-stroke mortality was associated with diabetes (SHR
1.60, 95% CI 1.54 to 1.65), hypertension/renal artery
disease (SHR 1.24, 95% CI 1.19 to 1.29) or other causes
(SHR 1.38, 95% CI 1.33 to 1.42) compared with glomerulonephritis/IgA nephropathy as the cause of ESKD. Those
with polycystic kidney disease were 24% less likely (SHR
0.76, 95% CI 0.72 to 0.80) to die of non-stroke compared
with those with glomerulonephritis/IgA nephropathy.
The unadjusted estimated risk of non-stroke death is
presented in online supplementary appendix 3.
Cumulative incidence of death
The estimated cumulative incidence of stroke mortality
since RRT was relatively low at 0.5% at 2 years, while the
non-stroke mortality was substantially higher at 15.5% at
2 years. At 5 years, the cumulative incidence increased to
0.9% for stroke and 36.8% for non-stroke mortality.
The cumulative incidence of stroke or non-stroke death
differed by sex, where females consistently had a higher
cumulative incidence (figure 2A). For stroke mortality,
the cumulative incidence at 2 years in males was 0.4%
and slightly higher in females at 0.6%. At 5 years, the sex
difference increased where the cumulative incidence
was 0.8% in males and 1.1% in females. For non-stroke
mortality, the cumulative incidence at 2 years was similar
in males at 17.6% and females at 17.4%. At 5 years, the
cumulative incidence remained similar at 43.3% in males
and 42.9% in females.
The cumulative incidence of stroke mortality decreased
over time, where those diagnosed with ESKD in 2006–
2013 had the lowest cumulative incidence during
follow-up (figure 2B). At 5 years, the cumulative incidence increased to 1.6% in ≤1995, 0.9% in 1996–2005
and 0.7% in 2006–2013. The cumulative incidence of
non-stroke mortality showed a similar trend. At 5 years,
the cumulative incidence increased to 46.3% in ≤1995,
38.0% in 1996–2005 and 30.4% in 2006–2013.
Discussion
This multinational study represents the largest study of
stroke mortality in people with ESKD to date, including
more than 381 000 PYs follow-up in 60 823 people starting
treatment for ESKD to evaluate risk factors associated
with stroke mortality in the Australia and New Zealand.
Our main finding was that women with ESKD were 41%
9
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Table 3 Continued

Open access

more likely to die from a stroke death compared with
men with ESKD. There was a decreasing trend in stroke
mortality risk over time, where patients with incident
ESKD in ≤1995 nearly twice as likely to die of stroke death
compared those starting ESKD treatment in 2006–2013.
We also found that those with cerebrovascular disease
were over twofold more likely to die of stroke compared
with those without cerebrovascular disease. Other factors
associated with an increased stroke mortality risk included
older age, normal BMI (vs overweight or obese BMI),
no previous malignancy, dialysis treatment compared
transplant and hypertension/renal artery disease or
diabetes as the cause of ESKD (vs glomerulonephritis/
IgA nephropathy). These risk factors highlight patients
with ESKD at greater risk of stroke death that could be
targeted in prevention strategies, particularly those with
cerebrovascular disease and females.
Our findings suggest a sex difference in stroke mortality
where women have at a greater risk of dying following a
stroke compared with men. Women have also been shown
to have a stroke incidence nearly twice that of men in the
Australian ESKD population. This is unlike the Australian
and New Zealand general population, where men have
a higher stroke incidence but comparable death rate
to women.20 21 Women may have confounding factors
that place them at a greater risk of stroke death. In the
general population, women are older at stroke onset,
have poorer outcomes after stroke and are more likely
10
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Figure 2 Estimate cumulative incidence of stroke and nonstroke deaths, by: (A) sex; (B) year period of ESKD diagnosis.
ESKD, end-stage kidney disease.

to have atrial fibrillation and hypertension.22–25 Alternatively, stroke prevention may not be implemented in
women as often as men. Previous studies in the general
population have found that women were less likely to be
prescribed antiplatelet therapy following an ischaemic
stroke and less frequently treated with an oral anticoagulant once diagnosed with atrial fibrillation.26 27 These gaps
in care may also prevail in the ESKD population, however,
no studies to date have specifically examined sex differences in stroke prevention among patients with ESKD.
Whether a lack of stroke prevention strategies or other
factors contribute to female patients with ESKD being at
a greater risk of stroke and stroke death still needs further
investigation.
Pre-existing cerebrovascular disease presents an opportunity for secondary prevention in the ESKD population,
either with existing or novel interventions. Our findings
are supported by previous studies of incident and recurrent strokes in the ESKD population.28–31 Studies in the
UK found that patients with ESKD with prior cerebrovascular disease were 4.5 times more at risk of incident
stroke.28 31 The mechanisms underlying cerebrovascular
disease and ESKD are likely due to a combination of
factors.32–35 First, CKD and cerebrovascular disease share
common risk factors, including older age, diabetes,
hypertension, obesity and smoking.33 34 Second, CKD-associated risk factors associated with CKD, such as chronic
inflammation, oxidative stress and uraemic retention
products, contribute to an excess risk of cerebrovascular
disease.32 35 Third, the dialysis process itself could lead to
an increased risk of stroke, such as hypoperfusion in HD
and glucose degradation in PD.9 36 In transplant patients,
graft function and the effect of albuminuria and eGFR may
also modify their risk of stroke death.10 Until now cerebrovascular disease prevention strategies implemented in
the ESKD population have mainly been based on stroke
interventions in the general population.33 37 38 Secondary
stroke prevention can either target modifiable risk factors,
such as hypertension and dyslipidaemia, or recommend
the use of an anticoagulant or antiplatelet.38 39 However,
the effectiveness of anticoagulant or antiplatelet therapy
in the ESKD population is unclear as patients with ESKD
are often under-represented or excluded from prevention trials.33 The few observational studies in anticoagulation therapy with warfarin suggested little evidence
of preventing ischaemic strokes and increased the risk
of major bleeding among patients with ESKD undergoing HD.40 41 Similarly, there is an absence of trial data
on the safety and effectiveness of stroke thrombolysis in
people with ESKD. A study examining nephrologist views
on stroke thrombolysis showed that most had concerns
about the bleeding risks and were uncertain about the
overall benefits in patients with ESKD.42 However, our
findings did suggest a decreasing trend in stroke mortality
risk over time where those initiating ESKD treatment in
recent years were less likely to die of stroke. This may
have arisen from improved stroke prevention interventions over time or better renal management. Further
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deaths, which does not allow time-varying covariates. We
were therefore unable to evaluate treatment modality
switches during follow-up. Finally, the sensitivity analyses
for risk factors associated with ischaemic stroke deaths
and haemorrhagic stroke deaths separately had substantially fewer stroke deaths than the overall main analysis.
In particular, there were only 108 ischaemic stroke deaths
which reduced the power to detect associated risk factors
in the model and increased impression of SHR estimates.
As such, we advise caution when interpreting these findings to suggest risk factors for ischaemic stroke deaths are
significantly different to haemorrhagic or all-cause stroke
deaths in patients with ESKD.
In conclusion, our analysis describes risk factors for
stroke mortality in the Australian and New Zealand ESKD
population. Most factors that led to an increased risk of
stroke death were non-modifiable, including older age,
female sex, year of ESKD and cause of ESKD. The sex
difference in stroke mortality in the ESKD population
is not seen in the general population. This raises questions as to whether female patients with ESKD have other
clinical characteristics that place them at a greater risk
or whether prevention strategies are not prescribed
in women as often as men. In addition, implementing
prevention strategies in those with prior cerebrovascular
disease has the potential to prevent secondary stroke in
patients with ESKD. It is unclear whether stroke prevention strategies are as effective in the ESKD population as
in the general population. Further research into the use
and effectiveness of stroke prevention in the ESKD population is needed to evaluate means of reducing stroke
mortality in those with cerebrovascular disease and in
females.
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research is still needed to assess whether the effectiveness
of secondary stroke prevention could be improved in the
ESKD population.
There were similarities and differences in the risk factors
associated with stroke and non-stroke mortality. Several
risk factors were associated with an increased risk for both
stroke and non-stroke death, including older age, earlier
year of ESKD, normal BMI compared with overweight
BMI, cerebrovascular disease, HD compared with transplant and diabetes or hypertension/renal artery disease
compared with glomerulonephritis/IgA nephropathy
as cause of renal failure. Female sex was only associated
with an increased risk of stroke death. While factors only
associated with an increased risk of non-stroke death were
underweight BMI compared with normal BMI, white
racial background, coronary or peripheral artery disease,
current or former smoker and glomerulonephritis/IgA
nephropathy compared with polycystic kidney disease as
cause of ESKD.
A major strength of our study was our large population-based patient sample that included the entire
ESKD population in Australia and New Zealand. We also
conducted several sensitivity analyses which were relatively consistent in the risk factors for stroke mortality.
This suggests our main analysis was fairly robust and reliable. However, there were several limitations to our study.
The limited data collected by ANZDATA did not allow us
to evaluate whether secondary stroke prevention interventions were being used in patients with ESKD. In addition, previous studies have shown family history of stroke,
blood pressure, atrial fibrillation and laboratory-related
data (such as haemoglobin) are strongly associated with
stroke, yet these data were not available in our patients
with ESKD as it is not systematically collected by the
ANZDATA registry. We also used data linkage to establish
the cause of death and date of death. Australian patients
were matched using probabilistic linkage to the national
death registry, while New Zealand patients were matched
via deterministic linkage. Probabilistic linkage can lead
to patients being incorrectly linked and, subsequently,
reporting an incorrect cause of death. The false positive
rate is estimated at 5 per 1000 or 0.5%.43 Mismatched
fact of death was high at 8% for Australian patients and
6% for New Zealand patients. The national death registries would not have captured patient deaths if they had
occurred outside of their registered country. However,
relatively few patients (0.8%) were considered lost to
follow-up in ANZDATA, where overseas death would be
possible. Hence, it is unlikely that patients with ESKD
moving overseas or between Australia and New Zealand
would have contributed to reduced linkage quality.
In addition, we used the underlying cause of death to
define stroke deaths. We would, therefore, expect these
stroke deaths to include patients who died of stroke and
stroke complications. Any misclassification bias would be
expected to be non-differential among people with ESKD
and the general population. We used the Fine and Gray
model to account for competing events of non-stroke
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